<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137020</url>
  </required_header>
  <id_info>
    <org_study_id>A1281117</org_study_id>
    <nct_id>NCT00137020</nct_id>
  </id_info>
  <brief_title>Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder</brief_title>
  <official_title>A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The primary objective is to compare effectiveness of ziprasidone treatment to current
      treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric
      Rating Scale (BPRS) scores versus baseline
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable will be change from baseline in Brief Psychiatric Rating Scale (BPRS) total score</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Clinical Global Impression Severity (CGI-S)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Improvement (CGI-I)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Positive and Negative Syndrome Scale (PANSS) Total</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in scores on the Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in scores on the MADRS Without Items 4, 5</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Global Assessment of Functioning (GAF)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Drug Attitude Inventory (DAI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Weight</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Prolactin And Lipid Levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Simpson Angus Scale (m-SAS) Total Score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Barnes Akathisia Scale (BAS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)— Movement Ratings Total Score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)— Global Judgment Of Severity Total Score</measure>
  </secondary_outcome>
  <enrollment>294</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of schizophrenia or schizoaffective disorder, using DSM-IV criteria.

          -  Currently receiving either haloperidol, olanzapine or risperidone within -/+ 25% of
             the recommended daily dose (as delineated by the medication's package insert

        Exclusion Criteria:

          -  Resistance to conventional antipsychotic drugs

          -  With antipsychotic agents other than olanzapine, risperidone or haloperidol at start
             of treatment regimen within 12 hours prior to first dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Larissa</city>
        <state>Mezourlo</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>15126</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jordan</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuwait</city>
        <zip>13041</zip>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Khobar</city>
        <zip>31451</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Garankuwa</city>
        <state>Gauteng</state>
        <zip>0208</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <state>Gauteng</state>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Noordheuwel, Krugersdorp</city>
        <state>Gauteng</state>
        <zip>1739</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bellair, Durban</city>
        <state>Kwa-Zulu Natal</state>
        <zip>4094</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pinetown, Durban</city>
        <state>Kwa-Zulu Natal</state>
        <zip>3600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Observatory, Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sisli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Greece</country>
    <country>Jordan</country>
    <country>Kuwait</country>
    <country>Lebanon</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281117&amp;StudyName=Clinical+Effect+Of+Cross+Titration+Of+Antipsychotics+With+Ziprasidone+In+Schizophrenia+Or+Schizioaffective+Disorder</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>August 11, 2006</last_update_submitted>
  <last_update_submitted_qc>August 11, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

